Australia markets closed

Biotron Limited (BIT.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.0810+0.0020 (+2.53%)
At close: 03:39PM AEDT

Biotron Limited

56 Delhi Road
Suite 3.3 North Ryde
Sydney, NSW 2113
Australia
61 2 9805 0488
https://www.biotron.com.au

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees

Key executives

NameTitlePayExercisedYear born
Dr. Michelle Miller BSc., GCertAppFin, MSc., Ph.D.MD & Executive Director387.43kN/AN/A
Mr. Peter James Nightingale B.Econ, CACompany Secretary120kN/A1957
Dr. Stephen L. Becker M.D.Chief Medical OfficerN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.

Description

Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. Its lead antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of SARS-CoV-2, HIV-1, and hepatitis C virus infections. The company was incorporated in 1999 and is based in Sydney, Australia.

Corporate governance

Biotron Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.